BRIEF published on 07/26/2024 at 14:09, 1 year 4 months ago Avemio AG Strengthens Buy-and-Build Strategy through Acquisition Acquisition Avemio AG Corporate Finance Equity Buy-and-Build
BRIEF published on 07/26/2024 at 14:06, 1 year 4 months ago Avemio AG Acquires 80% Stake in L.E.A Investment GmbH Acquisition Investment Avemio AG Corporate Finance L.E.A. Investment GmbH
PRESS RELEASE published on 07/26/2024 at 14:04, 1 year 4 months ago Avemio AG strengthens buy-and-build strategy through acquisition of Corporate Finance Boutique Avemio AG strengthens buy-and-build strategy through acquisition of Corporate Finance Boutique, expanding expertise in financing and M&A activities. Andreas Fischer to lead LEA Group Acquisition Avemio AG Corporate Finance Buy-and-build Strategy Andreas Fischer
PRESS RELEASE published on 07/26/2024 at 14:01, 1 year 4 months ago EQS-Adhoc: Avemio AG: Acquisition of an 80% stake in L.E.A Investment GmbH and its subsidiary Infinment GmbH Avemio AG acquires 80% stake in L.E.A Investment GmbH and Infinment GmbH. Transaction expected to close by 31 August 2024. Purchase price in mid-single-digit million Euro range Acquisition Avemio AG Share Transfer L.E.A Investment GmbH Infinment GmbH
BRIEF published on 07/15/2024 at 10:07, 1 year 4 months ago Avemio AG: Strategic Shift and Profit Margin Improvement Expected Media Technology EBITDA Avemio AG BUY Rating GBC AG
PRESS RELEASE published on 07/15/2024 at 10:02, 1 year 4 months ago Original-Research: Avemio AG (von GBC AG): BUY Avemio AG reported sales of €99.15 million for 2023 with an expected increase in profit margins. Strategic focus on media technology segment for customer loyalty and earnings quality improvement Media Technology Sales Growth Avemio AG Strategic Focus Profit Margins
BRIEF published on 06/28/2024 at 16:35, 1 year 5 months ago Avemio AG Publishes Audited Figures for 2023, Confirming Preliminary Results EBITDA Revenue 2023 Financial Year Avemio AG Annual Results
PRESS RELEASE published on 06/28/2024 at 16:30, 1 year 5 months ago Avemio AG published audited consolidated figures for 2023 – preliminary results confirmed Avemio AG releases audited 2023 annual report confirming preliminary results. Company reports stable revenue and break-even earnings EBITDA Revenue Avemio AG 2023 Annual Report Audited Consolidated Figures
BRIEF published on 06/24/2024 at 17:53, 1 year 5 months ago Avemio AG: Revenue and Earnings for 2023 Below Forecast According to Preliminary Figures EBITDA Revenue Forecast Avemio AG Preliminary Results Financial Outlook
PRESS RELEASE published on 06/24/2024 at 17:48, 1 year 5 months ago EQS-Adhoc: Avemio AG: Revenue and earnings for 2023 below forecast according to preliminary figures Avemio AG reports revenue and earnings for 2023 below forecast in preliminary results. Equity increases, financing secured for growth. Future acquisitions planned Revenue Avemio AG Financial Year 2023 Preliminary Results Earnings Growth Financing
Published on 12/05/2025 at 02:35, 3 hours 43 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 5 hours 18 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 13 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 18 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 2 hours 48 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 27 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 9 hours 53 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 3 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 8 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:00, 12 hours 18 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 33 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 34 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours 17 minutes ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago Declaration of voting rights at the end of November 2025
